Alnylam Pharmaceuticals
ALNY
#561
Rank
HK$348.42 B
Marketcap
HK$2,627
Share price
-0.94%
Change (1 day)
34.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2025 : HK$9.99 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$9.99 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2025-12-31HK$9.94 B-1.14%
2024-12-31HK$10.06 B-1.31%
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.53%
2020-12-31HK$4.04 B70.75%
2019-12-31HK$2.36 B907.21%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.69 M-25.84%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M2.46%
2004-12-31HK$55.96 M288.36%
2003-12-31HK$14.4 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novartis
NVS
HK$276.44 B 2,667.23%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$199.51 B 1,897.14%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$21.14 B 111.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
HK$9.76 B-2.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
HK$10.94 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$3.09 B-69.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$133.58 B 1,237.15%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$2.44 B-75.53%๐Ÿ‡บ๐Ÿ‡ธ USA